Elizabeth Garrett-Mayer to Doxorubicin
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Doxorubicin.
Connection Strength
0.312
-
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Score: 0.084
-
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009 Jan; 58(1):49-59.
Score: 0.067
-
Ductal access for prevention and therapy of mammary tumors. Cancer Res. 2006 Jan 15; 66(2):638-45.
Score: 0.057
-
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer. 2004 May; 40(8):1170-8.
Score: 0.051
-
Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Vet Comp Oncol. 2013 Dec; 11(4):306-15.
Score: 0.022
-
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol. 2009 Jun 10; 27(17):2816-22.
Score: 0.018
-
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer. Breast Cancer Res Treat. 2002 Nov; 76(2):145-56.
Score: 0.012